Abbott (NYSE:ABT) is a perennial outperformer that is a good buy, even when it's overpriced which it usually is. According to the excerpt below from the closing section of Seeking Alpha's 04/21/21 Wall Street Breakfast:
Abbott: A Refreshing Dip
Summary
- Abbott's price trajectory reflects its ability to adapt to the pandemic in real-time.
- The company alleged Q1 2021 revenue stumble presented a buying opportunity.
- Abbott's productive pandemic will seed its growth over the next decade.
Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.
Analyst’s Disclosure:I am/we are long ABT, ABBV, GILD. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I may buy or sell shares in any stock mentioned over the next 72 hours.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.